ArticleThorax2018
Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population.
Article in Thorax, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04714567 (Multidimensional Phenotyping of Severe Asthma Patients and Its Impact on Disease Control and Therapeutic Response - Analysis From the Portuguese Severe Asthma Registry), which is not on this map. Cited by 69 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multidimensional Phenotyping of Severe Asthma Patients and Its Impact on Disease Control and Therapeutic Response - Analysis From the Portuguese Severe Asthma Registry
Who cites it
69 citing papers in PubMed, 8 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Pooled it
- Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta-Analysis.Allergy · 2026Pooled it
- Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis.International archives of allergy and immunology · 2025Pooled it
- Epidemiology of severe asthma in children: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Pooled it
- Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis.The European respiratory journal · 2022Pooled it
- Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials.Respiratory research · 2019Pooled it
- Matching-adjusted indirect comparison of benralizumabThe European respiratory journal · 2018Pooled it
- A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis.The World Allergy Organization journal · 2026Article
- Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study.The World Allergy Organization journal · 2026Article
- Blood eosinophils as predictors of asthma exacerbations in adults: converging evidence from mendelian randomization, single-cell transcriptomics, and a two-center longitudinal cohort.Frontiers in immunology · 2026Article
- Characteristics of Adult Severe Uncontrolled Asthma Patients in Primary Care and Modifications in Prescribed Inhalation Treatments.Journal of asthma and allergy · 2026Article
- Understanding disease burden, challenges in current treatment strategies and call for action for management of severe asthma in Asia: a position statement from Asian respiratory experts.Frontiers in allergy · 2026Review
- Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review.The World Allergy Organization journal · 2025Article
- Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR).The World Allergy Organization journal · 2025Article
- Pre-biologic assessment of adherence in severe asthma and association with biologic continuation: a UK Severe Asthma Registry Study.BMJ open respiratory research · 2025Article
- Blood eosinophil reference values and determinants in a representative adult population.The journal of allergy and clinical immunology. Global · 2025Article
- Benralizumab and the integrated management of co-morbid severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps.Clinical and translational allergy · 2025Review
- Asthma and stem cell therapy.World journal of stem cells · 2025Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the prevalence of severe, uncontrolled eosinophilic asthma (SUEA) and associated costs.
aimsWe sought to determine the prevalence of SUEA and compare asthma-related healthcare resource use (HCRU) and associated costs with overall means for a general asthma population.
methodsThis cohort study evaluated anonymised medical record data (December 1989 through June 2015) from the Clinical Practice Research Datalink and the Optimum Patient Care Research Database to study UK patients with active asthma (diagnostic code and one or more drug prescriptions in the baseline year), aged 5 years and older, without concomitant COPD, and with recorded eosinophil count. SUEA was defined as two or more asthma attacks during 1 baseline year preceding a high blood eosinophil count (≥0.3×10
resultsOf 363 558 patients with active asthma and recorded eosinophil count, 64% were women, mean (SD) age was 49 (21) years; 43% had high eosinophil counts, 7% had two or more attacks in the baseline year and 10% were prescribed high-dosage ICS/LABA for 2 study years. Overall, 2940 (0.81%; 95% CI 0.78% to 0.84%) patients had SUEA. Total mean per-patient HCRU and associated costs were four times greater for SUEA versus all patients (HCRU and cost ratios 3.9; 95% CI 3.7 to 4.1).
conclusionsLess than 1% of patients in a general asthma population had SUEA. These patients accounted for substantially greater asthma-related HCRU and costs than average patients with asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.